Gleevec Could Get Higher Maximum Approved Dose
Novartis is seeking to increase the maximum approved dose of its oncologic Gleevec (imatinib mesylate) to 800 mg, Oncology President David Epstein said Jan. 20
Novartis is seeking to increase the maximum approved dose of its oncologic Gleevec (imatinib mesylate) to 800 mg, Oncology President David Epstein said Jan. 20